China – Medxy AI

Tropical Cyclones and Acute Coronary Syndromes: Unraveling the Cardiovascular Burden in Mainland China

By MedXY 09/12/2026

A nationwide Chinese study reveals that exposure to tropical cyclones increases acute coronary syndrome risk by 14%, delays treatment times, and disproportionately affects vulnerable populations. Coordinated public health and clinical strategies are essential to mitigate this environmental cardiovascular risk.

Cardiology news Public Health

Impact of a Community- and Family-Based Intervention on Blood Pressure Reduction in Rural China: Insights from a Cluster-Randomized Trial

By MedXY 08/28/2026

This cluster-randomized trial in rural China demonstrates that a coordinated community- and family-based intervention effectively lowers systolic blood pressure at the population level, highlighting the importance of sustained community engagement for hypertension control.

Clinical Updates news

Long-Term Exposure to PM2.5 Constituents and Coronary Heart Disease Risk in China: A Comprehensive Review

By MedXY 07/21/2026

This review synthesizes evidence linking long-term exposure to PM2.5 constituents—particularly elemental carbon, organic carbon, and nitrate—with increased coronary heart disease and acute myocardial infarction risks in China, emphasizing the need for targeted air pollution control.

news Oncology

Cancer Statistics in China: Current Landscape, Risk Factors, and Preventive Strategies

By MedXY 01/14/2026

This article reviews the epidemiological transition of cancer in China, highlighting incidence, mortality, survival trends, major modifiable risk factors, and national prevention and control efforts.

Diabetes & Endocrinology news

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial

By MedXY 11/17/2025

This phase 3 study demonstrates that adding tirzepatide to basal insulin significantly improves glycemic control in Chinese patients with type 2 diabetes, with a manageable safety profile.

news Ophthalmology

Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy

By MedXY 11/02/2025

A prospective phase IV open‑label Chinese study found cenegermin achieved corneal healing in 84.6% of stage 2/3 neurotrophic keratopathy patients at 8 weeks, with durable effects through 56 weeks and an acceptable safety profile.